All News

Abstr#0647 Toronto Lupus Clinic finds pericarditis in 20% of #SLE inception cohort, often with skin, heme, MSK, & renal involvement. Linked to younger age, White race, +SSB, & lower ACR/EULAR scores - Tx: GC, HCQ, AZA @RheumNow #ACR24

Akhil Sood MD AkhilSoodMD ( View Tweet)

Abstract #0614 What is the impact of Lupus on my quality of life? Consider using Lupus Impact Tracker (https://t.co/fJQe2uHicM) - high dose GC, comorbidities, and not actively working associated with worse impact on QoL - HCQ shows benefit @RheumNow #ACR24

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)

#0477 🌍 Global prevalence of RA-ILD ➡️21.38% (95% CI 0.15 - 0.29),33 studies, n=14,281 🔬 Higher RA-ILD risk in smokers, low-income regions, DMARD use. ⛔️Wide CI = heterogeneity main limitation 💡 Screening & lifestyle changes key for high-risk groups. #ACR24 @RheumNow

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

Harnessing power of AI in Rheumatology. Strengths and weaknesses of AI will need to be assessed. Amanda Nelson shares the limitation of AI @RheumNow #ACR24 https://t.co/G8FNVco7Qp

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

A study in difficult-to-treat (D2T) ankylosing spondylitis (AS) reveals distinct characteristics in patients, including: - Higher BMI - Increased comorbidities - Presence of EAMs - HLA-B27 positivity is linked to higher odds of being D2T, highlighting potential genetic… https://t.co/XcShdxSwhm

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Data from the EISER study show that IBD was significantly more prevalent in pts with r-axSpA than nr-axSpA. Makes sense in a way since longer dse duration may play a role. 🔶️THM - screen SpA pts for IBD; ask for GI symptoms @RheumNow #ACR24 abs554 https://t.co/Q6jeDUFa8Z

Links:

sheila RHEUMarampa ( View Tweet)
High PBO effect in PsA studies Abst#0772 from U. of Vienna analyzed PBO arms of PsA trials for bDMARDs and tsDMARDs on ACR response rates at week 12: 💡PBO rates significantly increased over time. 💡Recruitment patterns increasing in geographic areas with less affluent health… https://t.co/wAJnwjYkVe

Links:

Adela Castro AdelaCastro222 ( View Tweet)

Lots of ‘CARTS’, not enough ‘work horses’! There are now ~40 CAR-T protocols in #lupus incl many presentations at #ACR24 -most are uncontrolled -selection of pts is key. We need a pathway forward for reg approval & guidelines for studies! @RheumNow @ACRheum 18abst #OOO4 https://t.co/Mckwvn3Ffn

Links:

Janet Pope Janetbirdope ( View Tweet)
#0582🔬Challenges in Achieving PsA Disease Control ➡️n=2,093; 18% and 8% achieved minimal, very low disease activity respectively 🔑Higher QoL & monotherapy⬆️success; female sex, fatigue, spine pain⬇️outcomes. 🩺Unmet needs remain in PsA; tailored Rx needed #ACR24 @RheumNow

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/rO0ufturHW

Links:

Mike Putman EBRheum ( View Tweet)
Which lupus nephritis patients are at higher risk for CKD? #Abstract0624 shows coexisting tubulointerstitial inflammation/damage (TII/TID) on renal biopsy is linked to CKD progression (HR 2.667, 95% CI: 1.333-5.335) Risk high among Class III, IV, V and eGFR > 30 @RheumNow #ACR24

Akhil Sood MD AkhilSoodMD ( View Tweet)

#0501 💥 JAKi & TNFi show faster short-term RA improvement (3months) compared to IL-6i & ABA ➡️n=9590(3049 JAKi, 4606 TNFi, 1284 IL-6, 651 ABA), 14 registers 🕒 JAKi, TNFi improved CDAI, pain, function in 1st two months then stabilised 💡Long-term data needed #ACR24 @RheumNow https://t.co/4yzeAAkGjq

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
The rising placebo response rates in PsA trials are linked to global recruiting patterns, with more studies in less affluent countries. Limited access to healthcare may drive this trend, highlighting the need for awareness among stakeholders. Plenary Abstr#0722… https://t.co/FplpSlIamR https://t.co/NIp76IS6TZ

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
More evidence: persistence of imaging abnormalities is probably NOT an adequate metric of LVV tx failure Boiardi et al - 87% TAK/LV-GCA pt w persistent dz on imaging despite clinical remission, TAK>GCA PET avidity more persistent in GCA @RheumNow #ACR24 Abstract 1617

Brian Jaros, MD Dr_Brian_MD ( View Tweet)

Which immunomodulators dampen recombinant zoster vaccine immunogenicity? In this 🇧🇷 study in autoimmune dx patients, overrepresented in non-responders are: - rituximab pts - 'combined therapy' strategies needed for them but reassuring for the others! #ACR24 ABST0248 @RheumNow https://t.co/he1ICa9WZg

Links:

David Liew drdavidliew ( View Tweet)
Kerschbaumer et al. Rising placebo rates in PsA RCTs appear linked to changes in global recruitment patterns. Dramatic relationship between GNI and placebo response rate. Crucial information for properly planning future trials @RheumNow #ACR24 Abstr#0772 https://t.co/PtHs2RXe0f https://t.co/OKG6czQrYD

Links:

Richard Conway RichardPAConway ( View Tweet)
#Frailty leads to poor outcomes and occurs earlier in RA patients. Different tools measure frailty as a phenotype vs. deficit accumulation. Discover the role of frailty in ED from #LancetRheum Ageing Series by Drs. Sarah Lieber and @KWyshamMD ! #ACR24 @RheumNow ABST#1334 https://t.co/25XQBDQMCo

Links:

Jiha Lee JihaRheum ( View Tweet)
Location of research matters Ab#0772 Global recruiting patterns impact PBO in PsA PBO results improve w time - 0.9%/year More globalization of trials w time Gross nation index (GNI) neg ass w ACR20 - inclusion of less affluent controls affects higher PBO response @RheumNow #ACR24

Eric Dein ericdeinmd ( View Tweet)

Poster#0035 🚨Postpartum RA Risk & Mucosal Immunity 👩‍🍼Elevated anti-CCP-IgG in cervicovaginal fluid of postpartum women (n=25) vs. controls. 🧪Local anti-CCP production despite negative serum ❓Childbirth-associated mucosal inflammation may drive RA onset. #ACR24 @RheumNow https://t.co/plvtyJDSY1

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
To GLP or not to GLP—is it still even a question in obesity management given pluripotent benefits 👇🏻 Dr. Louis Aronne recommends ➡️ Start low and titrate slow 💊 ➡️ Provide pt education on GI side effects, ondansetron effective for nausea #ACR24 @RheumNow https://t.co/SzVg2dopCo

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
×